Live single cell mass spectrometry reveals cancer‐specific metabolic profiles of circulating tumor cells

Abouleila, Yasmine; Onidani, Kaoru; Ali, Ahmed; Shoji, Hirokazu; Kawai, Takayuki; Lim, Chwee Teck; Kumar, Vinit; Okaya, Shinobu; Kato, Ken; Hiyama, Eiso; Yanagida, Toshio; Masujima, Tsutomu; Shimizu, Yoshihiro; Honda, Kazufumi

doi:10.1111/cas.13915

Cited by 96 publications

(75 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Yet, it is the development of single-cell technologies during the past decade that has enabled a comprehensive interrogation of CTCs from patients with various cancer types. Combined with next-generation sequencing (NGS) and mass cytometry technologies, it is now possible to characterize the genome, transcriptome, methylome [18], and proteome [19] of individual cells. The recent development of a single-cell RNA-seq platform based on a hydrodynamic barcoding technique (Hydro-Seq) also shows a promising efficiency for wholetranscriptome analysis of CTCs [20].…”

Section: Molecular Analysis Of Ctcsmentioning

confidence: 99%

Tracking cancer progression: from circulating tumor cells to metastasis

2020

View full text Add to dashboard Cite

The analysis of circulating tumor cells (CTCs) is an outstanding tool to provide insights into the biology of metastatic cancers, to monitor disease progression and with potential for use in liquid biopsy-based personalized cancer treatment. These goals are ambitious, yet recent studies are already allowing a sharper understanding of the strengths, challenges, and opportunities provided by liquid biopsy approaches. For instance, through single-cellresolution genomics and transcriptomics, it is becoming increasingly clear that CTCs are heterogeneous at multiple levels and that only a fraction of them is capable of initiating metastasis. It also appears that CTCs adopt multiple ways to enhance their metastatic potential, including homotypic clustering and heterotypic interactions with immune and stromal cells. On the clinical side, both CTC enumeration and molecular analysis may provide new means to monitor cancer progression and to take individualized treatment decisions, but their use for early cancer detection appears to be challenging compared to that of other tumor derivatives such as circulating tumor DNA. In this review, we summarize current data on CTC biology and CTC-based clinical applications that are likely to impact our understanding of the metastatic process and to influence the clinical management of patients with metastatic cancer, including new prospects that may favor the implementation of precision medicine. Publisher's NoteSpringer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

show abstract

Section: Molecular Analysis Of Ctcsmentioning

confidence: 99%

Tracking cancer progression: from circulating tumor cells to metastasis

2020

View full text Add to dashboard Cite

show abstract

“…Another similar integration with 3D holography has allowed for achieving absolute quantitation of cellular metabolites on the subcellular level 16 . Additionally, integration with flow cytometry has allowed for the uncovering of metabolic biomarkers in single circulating tumor cells of neuroblastoma cancer patients 17,18 .…”

Section: Discussionmentioning

confidence: 99%

An Integrated Raman Spectroscopy and Mass Spectrometry Platform to Study Single-Cell Drug Uptake, Metabolism, and Effects

Ali

Abouleila

Germond

2020

JoVE

Self Cite

View full text Add to dashboard Cite

Cells are known to be inherently heterogeneous in their responses to drugs. Therefore, it is essential that single-cell heterogeneity is accounted for in drug discovery studies. This can be achieved by accurately measuring the plethora of cellular interactions between a cell and drug at the single-cell level (i.e., drug uptake, metabolism, and effect). This paper describes a single-cell Raman spectroscopy and mass spectrometry (MS) platform to monitor metabolic changes of cells in response to drugs. Using this platform, metabolic changes in response to the drug can be measured by Raman spectroscopy, while the drug and its metabolite can be quantified using mass spectrometry in the same cell. The results suggest that it is possible to access information about drug uptake, metabolism, and response at a single-cell level.

show abstract

“…By exploiting this property, CTCs from several solid cancer models have been successfully distinguished from surrounding blood cells 83 . Similarly, a mass spectrometry approach combined with microfluidics platform has recently been used to efficiently discriminate colorectal cancer patients from those with gastric cancer, based on their CTCs metabolomic profile 84 …”

Section: Marker‐based Approaches For Ctcs Identificationmentioning

confidence: 99%

Perspectives on liquid biopsy for label‐free detection of “circulating tumor cells” through intelligent lab‐on‐chips

Miccio

Cimmino

Kurelac

et al. 2020

VIEW

View full text Add to dashboard Cite

Circulating tumor cells (CTCs) are rare tumor cells released from primary, metastatic, or recurrent tumors in the peripheral blood of cancer patients. CTCs isolation from peripheral blood and their molecular characterization represent a new marker in cancer screening, a diagnostic tool called “liquid biopsy” (LB). Compared to traditional tissue biopsy that is invasive and does not reveal tumor heterogeneity, LB is noninvasive and reflects in “real‐time” tumor dynamism and drug sensitivity. In the frame of LB, a new paradigm based on single‐cell and label‐free analysis based on morphological analysis is emerging. Here, we review the latest research developments in this emerging vision of LB. In particular, we survey and discuss recent improvements in microfluidics, imaging label‐free diagnosis and cell classification by artificial intelligence and how to combine them to realize an intelligent platform based on lab‐on‐chip technology. This prospect appears to open up promising and intriguing new scenarios for cancer management through single‐cell analysis that will revolutionize the future of early cancer diagnosis and therapeutic choice with disruptive impact on the society.

show abstract

Live single cell mass spectrometry reveals cancer‐specific metabolic profiles of circulating tumor cells

Cited by 96 publications

References 77 publications

Tracking cancer progression: from circulating tumor cells to metastasis

Tracking cancer progression: from circulating tumor cells to metastasis

An Integrated Raman Spectroscopy and Mass Spectrometry Platform to Study Single-Cell Drug Uptake, Metabolism, and Effects

Perspectives on liquid biopsy for label‐free detection of “circulating tumor cells” through intelligent lab‐on‐chips

Contact Info

Product

Resources

About